Skip to content

Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families

Family Centered Advanced Care Planning (FCACP)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00723476
Enrollment
82
Registered
2008-07-28
Start date
2005-09-30
Completion date
2008-09-30
Last updated
2015-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Quality of Life, Adolescent, Advance Care Planning, Palliative Care, End-of-Life Care, HIV/AIDS, Psychological Adjustment

Brief summary

This study will examine the efficacy of Family Centered Advance Care Planning in enhancing quality of life, integrating effective end-of-life care, and preventing depression and anxiety among HIV infected adolescents and their family members.

Detailed description

More than 30,000 adolescents in the United States die annually from the effects of chronic illnesses. The anxiety from facing a terminal illness often hinders adolescents in making decisions about their own end-of-life (EOL) care. Although minors' preferences are not legally binding, legislature, research, and professional guidelines all recommend that adolescent patients become involved in EOL decisions as part of routine intervention while they are stable. Family Centered Advance Care Planning (FCACP) is an intervention that facilitates EOL discussion among adolescents, their families, and their care providers. This pilot study will examine FCACP's effects on adaptive coping, psychological adjustment, quality of life, and plans and actions in HIV infected adolescents. The study will also provide feedback used for improving the FCACP Web site. This study will include HIV or AIDS infected adolescents ranging in age from 14 to 21 who will jointly enroll with a selected surrogate older than 21. The adolescent/surrogate pairs will be randomly assigned to receive either the FCACP intervention or a health education control intervention. Pairs not immediately ready to participate will form an observational group. Pairs in the FCACP group will meet with a trained facilitator weekly for a 60- to 90-minute session for a total of 3 weeks. During the first session, participants will take the Lyon Advance Care Planning Survey. The second session will consist of the Respecting Choices Interview, where patients will discuss treatment preferences. The Family Problem-Solving session will be last, culminating with the patient's completion of an advance directive. The control groups will follow the same meeting schedule, but will receive health education sessions, not FCACP sessions. Standardized self-report measures will be administered upon entry, after completion of the sessions, and at a 3-month follow up. Usage data will also be analyzed regarding feasibility and acceptability of FCACP as a standard treatment.

Interventions

BEHAVIORALFamily Centered Advanced Care Planning (FCACP) sessions

FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.

BEHAVIORALHealth education control sessions

Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
Maureen Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Adolescent Eligibility Criteria: * Diagnosed with HIV/AIDS * Between the ages of 14 and 21 years * Aware of his or her HIV status * Able to speak English * Intelligence Quotient (IQ) greater than 69 (all patients have IQ testing results in chart as part of standard of care) * Consent from the legal guardian if between ages of 14 and 17 * Consent from the surrogate if between ages of 18 and 21 * Assent from adolescent aged 14 to 17 * Consent from adolescent aged 18 to 21 Legal Guardian Eligibility Criteria (for guardians of adolescents aged 14 to 17): * Adolescent is willing to discuss problems related to HIV with him/her * Age 21 or older * Able to speak English * Legal guardian Surrogate Eligibility Criteria: * Selected by adolescent aged 18 to 21 * Age 21 or older * Willing to discuss problems related to HIV and EOL * Able to speak English

Exclusion criteria

For All Participants: * Depression in the moderate to severe range on Beck Depression Inventory * Unaware of HIV status of self, or if proxy, of adolescent * Presence of HIV dementia, determined at screening using the HIV Dementia Scale * Active homicidality or suicidality, determined at baseline screening by psychologist or researcher

Design outcomes

Primary

MeasureTime frame
Improved mental health outcomes (e.g., decreased anxiety, depression), improved quality of life, and improved plans and actions (e.g., communication with primary health care provider, an advanced directive in the medical chart)Measured at Month 3 of follow-up

Secondary

MeasureTime frame
Improved congruence about end-of-life care between adolescents and family, using the Statement of Treatment PreferencesMeasured immediately post-treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026